Manila Times Business
Oriva Therapeutics appoints Dr Agnès Arbat as CEO to advance clinical-stage women’s health pipeline
Oriva is developing innovative medicines for chronic gynaecological diseases and is backed by pre-seed financing from Asabys Partners’ Sabadell Asabys II fundDr Arbat brings over 25 years’ pharma industry experience, including roles in women’s health at Bayer and OrganonOriva’s lead asset, ORV-362 - a non-hormonal, disease-modifying, first-in-class therapy for endometriosis - is already in Phase I clinical trials BARCELONA, Spain, June 11, 2026 (GLOBE NEWSWIRE) -- Oriva Therapeutics ("Oriva”), a
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Colombia moves to ban female genital mutilation
1h ago
Alas Pilipinas bows out of AVC Women’s Cup medal contention after loss to Taiwan
1h ago
Family lawyer seeks immigration watchlist order vs Ateneo coach in Aurora drowning case
1h ago
Global Fatty Liver Day 2026 builds on WHO Momentum to Drive Urgent Action on Steatotic (fatty) Liver Disease
1h ago